The value of methotrexate in dermatomyositis.
Zieglschmid-Adams
M E
ME
Pandya
A
A
Cohen
S B
SB
Sontheimer
R D
RD
D000284:Administration, Oral; D000931:Antidotes / Q000627:therapeutic use; D001219:Aspartate Aminotransferases / Q000097:blood; D001706:Biopsy; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003882:Dermatomyositis / Q000188:drug therapy*; D005492:Folic Acid / Q000627:therapeutic use; D006397:Hematinics / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012307:Risk Factors
D000931:Antidotes; D003879:Dermatologic Agents; D006397:Hematinics; D005492:Folic Acid; D001219:Aspartate Aminotransferases; D002955:Leucovorin; D008727:Methotrexate